Aia Group LTD Bei Gene, Ltd. Transaction History

Aia Group LTD

$3.67 Billion
Q3 2024

A detailed history of Aia Group LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Aia Group LTD holds 21,665 shares of BGNE stock, worth $4.16 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

21,665

Previous 21,665 -0.0%

Holding current value

$4.16 Million

Previous $3.09 Million 57.41%

% of portfolio

0.13%

Previous 0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$129.52 - $174.32 $410,319 - $552,245	3,168 Added 17.13%	21,665 $3.09 Million
Q1 2024 May 06, 2024	BUY	$141.8 - $181.47 $734,665 - $940,196	5,181 Added 38.91%	18,497 $2.89 Million
Q4 2023 Jan 31, 2024	BUY	$158.67 - $201.58 $255,776 - $324,946	1,612 Added 13.77%	13,316 $2.4 Million
Q3 2023 Nov 01, 2023	BUY	$179.87 - $225.13 $242,644 - $303,700	1,349 Added 13.03%	11,704 $2.11 Million
Q2 2023 Jul 28, 2023	BUY	$178.3 - $266.78 $1 Million - $1.5 Million	5,621 Added 118.74%	10,355 $1.85 Million
Q1 2023 Apr 28, 2023	BUY	$215.53 - $274.5 $234,496 - $298,656	1,088 Added 29.84%	4,734 $1.02 Million
Q4 2022 Jan 31, 2023	SELL	$125.51 - $229.3 $59,617 - $108,917	-475 Reduced 11.53%	3,646 $801,000
Q3 2022 Nov 04, 2022	BUY	$131.8 - $202.24 $35,717 - $54,807	271 Added 7.04%	4,121 $556,000
Q2 2022 Aug 11, 2022	BUY	$121.11 - $216.05 $52,682 - $93,981	435 Added 12.74%	3,850 $623,000
Q1 2022 May 06, 2022	BUY	$146.52 - $269.56 $348,571 - $641,283	2,379 Added 229.63%	3,415 $644,000
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $257,508 - $403,356	1,036 New	1,036 $281,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aia Group LTD with notifications on news.

Account